Press Release

PhRMA Statement on Precision Medicine Initiative

PhRMA February 10, 2015

Washington, D.C. (January 21, 2015) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO, John J. Castellani released the following statement:

“We commend the administration’s commitment to advancing the field of precision, or personalized, medicine. The biopharmaceutical research sector is strongly committed to researching and developing personalized medicines, and ensuring patients can gain timely access to them. Recent advances in diseases such as cancer and cystic fibrosis are delivering on the promise of targeted treatments, and between 12 and 50 percent of all compounds currently being researched by the industry are potential personalized medicines. These advances hold great promise in improving patient outcomes and controlling costs by targeting the right medicines to the right patients. PhRMA is committed to advancing scientific, regulatory, and reimbursement policies that support development of and patient access to personalized medicines and other new treatments, and we look forward to working with the administration, as well as leaders on both sides of the aisle in Congress who are developing reforms in this important area.”

About PhRMA

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $550 billion in the search for new treatments and cures, including an estimated $51.1 billion in 2013 alone. 

Find PhRMA Online: 

Website –

Facebook –

Blog –

Twitter –

YouTube –

For information on how innovative medicines save lives, visit:

For information on access to medicines, visit:

For information on the Partnership for Prescription Assistance, visit:

For information on ensuring the flow of medicines during public health emergencies, visit: